voxilaprevir voxilaprevir voxilaprevir is a hepatitis c virus (hcv) nonstructural (ns) protein 3/4a protease inhibitor (by gilead) that is used in combination with sofosbuvir and velpatasvir. the combination has the trade name vosevi and received a positive opinion from the european committee for medicinal products for human use in june 2017. voxilaprevirclinical datatrade namesvosevi (combination with sofosbuvir and velpatasvir)identifiers iupac name (1r,18r,20r,24s,27s,28s)-n-carbamoyl}cyclopropyl]-28-ethyl-13,13-difluoro-7-methoxy-24-(2-methyl-2-propanyl)-22,25-dioxo-2,21-dioxa-4,11,23,26-tetraazapentacyclononacosa-3(12),4,6,8,10-pentaene-27-carboxamide cas number1535212-07-7pubchem cid89921642chemspider44209500unii0570f37359keggd10899pdb ligandl9p (pdbe, rcsb pdb)chemical and physical dataformulac40h52f4n6o9smolar mass868.94 g·mol−13d model (jsmol)density1.4±0.1 g/cm3 smiles cc12cn(1c(=o)n3(c3c(f)f)c(=o)ns(=o)(=o)c4(cc4)c)c(=o)(nc(=o)o5c5ccccc(c6c(nc7cc(ccc7n6)oc)o2)(f)f)c(c)(c)c inchi inchi=1s/c40h52f4n6o9s/c1-7-22-27-19-50(28(22)32(51)48-39(18-23(39)31(41)42)35(53)49-60(55,56)38(5)14-15-38)34(52)30(37(2,3)4)47-36(54)59-26-16-20(26)10-8-9-13-40(43,44)29-33(58-27)46-25-17-21(57-6)11-12-24(25)45-29/h11-12,17,20,22-23,26-28,30-31h,7-10,13-16,18-19h2,1-6h3,(h,47,54)(h,48,51)(h,49,53)/t20-,22-,23+,26-,27+,28+,30-,39-/m1/s1key:mzblzlwxubzhsl-fznjkfjksa-n on 18 july 2017, vosevi was approved by the us food and drug administration.